New five-year data from the phase III CheckMate 274 trial is giving patients and doctors more confidence in using nivolumab (Opdivo) after surgery for high-risk muscle-invasive urothelial carcinoma, the most common type of bladder cancer. Researchers found that patients who received nivolumab after surgery stayed cancer-free significantly longer than those who didn’t receive the treatment. […]

When bladder cancer treatment ends, follow-up care begins. The appointments after treatment are an essential part of your ongoing care. Bladder cancer has one of the highest recurrence rates, which means monitoring closely after treatment gives you the best chance of catching changes early. Your exact schedule may vary based on your stage, grade, and […]

Being told that bladder cancer has returned can bring up a flood of questions and emotions. What does recurrence mean, and what do the next steps look like? Bladder cancer recurrence means that cancer has returned after treatment. This may look like a new tumor forming in the bladder, cancer coming back with different characteristics, […]

After a bladder cancer diagnosis, you may hear about treatment options including surgery, chemotherapy, radiation, immunotherapy, or targeted therapy. Alongside these established approaches, clinical trials may provide additional opportunities to explore. In bladder cancer, clinical trials are important because they’re driving innovations in personalized treatments, surgical techniques, and immunotherapy. Joining a trial may provide access […]